Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,206
  • Shares Outstanding, K 131,101
  • Annual Sales, $ 5,530 K
  • Annual Income, $ -25,140 K
  • 60-Month Beta 0.64
  • Price/Sales 10.90
  • Price/Cash Flow N/A
  • Price/Book 2.91
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.91
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +89.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3660 +36.07%
on 05/04/20
0.5970 -16.58%
on 05/26/20
+0.1130 (+29.35%)
since 04/24/20
3-Month
0.2112 +135.80%
on 03/17/20
0.7890 -36.88%
on 02/28/20
+0.1880 (+60.65%)
since 02/26/20
52-Week
0.2112 +135.80%
on 03/17/20
1.6200 -69.26%
on 05/28/19
-0.7420 (-59.84%)
since 05/24/19

Most Recent Stories

More News
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

, /PRNewswire/ -- . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients...

BIOC : 0.4980 (-1.39%)
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories

, /PRNewswire/ -- . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients...

BIOC : 0.4980 (-1.39%)
Biocept Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Liquid Biopsy Industry Outlook 2020-2030 by Product, End-user, Clinical Application, Region, Country

, /PRNewswire/ -- The report has been added to offering.

BIOC : 0.4980 (-1.39%)
MYGN : 14.27 (-3.16%)
QGEN : 43.26 (+0.63%)
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Announces CE-IVD Mark and Availability of its Target Selector(TM) EGFR Molecular Assay Kit in Europe

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector(TM) Technology Validated for Use in Both Tissue and Blood Samples

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.4980 (-1.39%)
Biocept to Begin COVID-19 Testing

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)
Brazil Patent Granted for Biocept's Target Selector(TM) Oncogene Mutation Enrichment and Detection Platform

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.4980 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade BIOC with:

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

2nd Resistance Point 0.6413
1st Resistance Point 0.5697
Last Price 0.4980
1st Support Level 0.4537
2nd Support Level 0.4093

See More

52-Week High 1.6200
Fibonacci 61.8% 1.0818
Fibonacci 50% 0.9156
Fibonacci 38.2% 0.7494
Last Price 0.4980
52-Week Low 0.2112

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar